AGP Executive Report
Last update: 8 hours agoHealthcare AI: NTT Data and Taiwan’s TwHealth Nexus will explore AI medical and imaging tools, alongside systems to integrate health data. Vaccination: Taiwan’s flu and COVID-19 campaigns have delivered more than 1.3 million flu doses and 482,000 COVID-19 doses in six days; officials urge eligible people to get both as flu cases and deaths remain high. Cancer Care: A Taiwan-led study found lower two-year mortality among immunotherapy patients taking SSRIs than among those taking benzodiazepines. The researchers caution that the observational findings do not prove antidepressants caused the difference. Drug Development: Ono Pharma secured rights in Taiwan and other Asian markets to develop Biohaven’s investigational antibody-degrading treatments, including a Phase 3 candidate for Graves’ disease. Reproductive Health: Taiwan’s birth gender ratio moved closer to natural balance, but low birth rates persist as the government expands fertility-treatment subsidies.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
